Scott Koenig

This inventor holds 58 USPTO granted patents and 26 published patent applications, plus 7 CIPO patents and 15 EPO patents, primarily in Bispecific Antibodies (CPC class C07K). Top assignees: Macrogenics, Inc., Medimmune Limited, Duke University. Active years: 1995-2026.

USPTO Granted Patents = 58 (Patent Applications = 26)

% Patents Active = 70.7

CIPO Patents = 7 (Patent Applications = 14)

EPO Patents = 15 (Patent Applications = 29)

Average Co-Inventor Count = 2.9

ph-index = 20

Forward Citations = 1,060(Granted Patents)

Forward Citations (Not Self Cited) = 947(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Stewart Manor, NY (US) (1995)
Brooklyn, NY (US) (2014 - 2015)
Rockville, MD (US) (2002 - 2024)

Company Filing History:

St. Jude Children's Research Hospital

patents

5. 2 out of 1,326

The University of North Carolina at Chapel Hill

patents

6. 1 out of 959

The University of British Columbia

patents

7. 4 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 1995-2026

Loading Chart...

Areas of Expertise:

Bispecific Molecules

PD-1 Binding

Cancer Treatment

Immunoglobulins

Fc Regions

Autoimmune Disorders

Diabodies

HIV-1 Envelope

Combination Therapy

Immunoreactivity

Vaccine Development

Antibody Administration

58 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12600779 - LAG-3-Binding Molecules and Methods of Use Thereof (2026-04-14),

2. 12534531 - PD-1-BINDING MOLECULES AND METHODS OF USE THEREOF (2026-01-27),

3. 12173051 - Bispecific molecules comprising an HIV-1 envelope targeting arm (2024-12-24),

4. 11858991 - LAG-3-binding molecules and methods of use thereof (2024-01-02),

5. 11840571 - Methods of using bispecific molecules having immunoreactivity with PD-1 and CTLA-4 (2023-12-12),

6. 11787871 - Methods for the treatment of disease using immunoglobulins having fc regions with altered affinities for FcgammaRactivating and FegammaRinhibiting (2023-10-17),

7. 11639386 - Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof (2023-05-02),

8. 11623959 - PD-1-binding molecules and methods of use thereof (2023-04-11),

9. 11421031 - Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof (2022-08-23),

10. 11174315 - Combination therapy for the treatment of cancer (2021-11-16),

11. 11098119 - Covalently bonded diabodies having immunoreactivity with PD-1 and LAG-3, and methods of use thereof (2021-08-24),

12. 11078279 - Combination therapy for the treatment of cancer (2021-08-03),

13. 11072653 - LAG-3-binding molecules and methods of use thereof (2021-07-27),

14. 10954301 - Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof (2021-03-23),

15. 10730947 - Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof (2020-08-04),

Title: The Innovative Journey of Scott Koenig

Introduction: Scott Koenig, a talented inventor based in Rockville, MD, has made significant contributions to the field of technology through his creative and groundbreaking ideas.

Latest Patents: Scott Koenig holds several patents in various technological domains, including artificial intelligence, renewable energy, and medical devices, showcasing his versatility and ingenuity in the innovation landscape.

Career Highlights: With a career spanning over two decades, Scott Koenig has worked with leading tech companies, where he spearheaded research and development projects that have resulted in cutting-edge inventions and solutions that have positively impacted industries and society as a whole.

Collaborations: Throughout his career, Scott Koenig has collaborated with top researchers, engineers, and scientists, both nationally and internationally, fostering a culture of innovation and knowledge exchange that has led to groundbreaking discoveries and advancements in technology.

Conclusion: Scott Koenig's passion for innovation, coupled with his dedication to pushing the boundaries of what is possible, continues to inspire the next generation of inventors and entrepreneurs to pursue their ideas fearlessly and make a lasting impact on the world.